Verdence Capital Advisors LLC Has $333,000 Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Posted by on Apr 2nd, 2023

Verdence Capital Advisors LLC trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,169 shares of the company’s stock after selling 130 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Henry Schein were worth $333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ronald Blue Trust Inc. acquired a new position in Henry Schein during the 2nd quarter worth approximately $37,000. Dark Forest Capital Management LP purchased a new stake in shares of Henry Schein in the second quarter worth approximately $34,000. Ellevest Inc. raised its stake in shares of Henry Schein by 231.8% in the third quarter. Ellevest Inc. now owns 564 shares of the company’s stock worth $37,000 after purchasing an additional 394 shares during the last quarter. Guardian Wealth Advisors LLC purchased a new stake in shares of Henry Schein in the third quarter worth approximately $51,000. Finally, Godsey & Gibb Inc. purchased a new stake in shares of Henry Schein in the fourth quarter worth approximately $64,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $81.54 on Friday. The stock has a fifty day simple moving average of $81.77 and a two-hundred day simple moving average of $77.77. Henry Schein, Inc. has a 1-year low of $64.75 and a 1-year high of $92.68. The firm has a market cap of $10.70 billion, a price-to-earnings ratio of 20.96, a price-to-earnings-growth ratio of 1.84 and a beta of 0.80. The company has a current ratio of 1.79, a quick ratio of 0.91 and a debt-to-equity ratio of 0.25.

Henry Schein (NASDAQ:HSIC – Get Rating) last posted its earnings results on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.14. The firm had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 earnings per share. Analysts anticipate that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Insiders Place Their Bets

In other Henry Schein news, Director Kurt P. Kuehn sold 1,909 shares of the stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total transaction of $147,871.14. Following the sale, the director now owns 15,675 shares in the company, valued at $1,214,185.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Philip A. Laskawy sold 6,405 shares of the stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $78.74, for a total value of $504,329.70. Following the sale, the director now owns 26,239 shares in the company, valued at $2,066,058.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kurt P. Kuehn sold 1,909 shares of the stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the sale, the director now owns 15,675 shares in the company, valued at approximately $1,214,185.50. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several analyst reports. Morgan Stanley lowered their price objective on Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research note on Tuesday, February 21st. Piper Sandler upped their target price on Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a report on Monday, February 6th. Barrington Research reduced their target price on Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a report on Friday, February 17th. StockNews.com lowered Henry Schein from a “buy” rating to a “hold” rating in a report on Friday. Finally, UBS Group upped their target price on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a report on Tuesday, March 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $85.89.

Henry Schein Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.

Further Reading

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.